Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Li
To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
| Condition(s) | Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC |
| Who can participate | Inclusion Criteria: * Age 18-75 years old; Histologically or cytologically confirmed as limited-stage small cell lung cancer (T1-3N0-1M0); All lesions of the patient (including primary lesions, lymph nodes/metastatic lesions assessed as metastases) must be jointly evaluated by surgeons, radiotherapists, and radiologists to be surgically resectable; Subjects must have measurable target lesions (according to RECIST 1.1 standards); ECOG performance status score 0-1; No history of other malignant tumors; No previous anti-tumor treatment such as surgery, radiotherapy, chemotherapy, immunotherapy, etc. related to small cell lung cancer; Patients must have sufficient cardiopulmonary function: FEV1 and DLCO of patients are ≥50% of the predicted value, echocardiography indicates LVEF ≥55%, and no c |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Zhejiang Cancer Hospital |
| Locations | Hangzhou, Zhejiang, China |
| Start date | 2024-07-24 |
| NCT ID | NCT06562920 |
| Official listing | https://clinicaltrials.gov/study/NCT06562920 |